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This review tackles the issues related to disease burden caused by cervical cancer (CC) and its precursor (CIN)
lesions in Brazil. A special focus is given to new technologies with potential to interfere with the development of
CC by reducing the high-risk human papillomavirus (hr-HPV)-induced lesions that remain a major public health
burden in all developing countries where organized screening programs do not exist. Globally, 85 % of all incident
CC and 50 % of CC deaths occur in the developing countries. Unfortunately, most regions of Brazil still demonstrate
high mortality rates, ranking CC as the second most common cancer among Brazilian women. Recently, CC screening
programs have been tailored in the country to enable early detection of CC precursor lesions and thereby reduce cancer
mortality. A combination of HPV testing with liquid-based cytology (LBC) seems to be a promising new approach in CC
screening, with high expectation to offer an adequate control of CC burden in this country.
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Short overview on human papillomavirus (HPV)
Human papillomavirus (HPV) is a non-enveloped small
(8000 bp) DNA-virus with circular double-stranded DNA,
showing a specific tropism for human epithelial cells both
in the skin and mucous membranes [1, 2]. Since the 1970’s,
evidence has been emerging causally linking HPV with dif-
ferent human neoplastic lesions. Until now, 200 HPV types
have been fully characterized, comprising both i) cutaneous
HPV types causing benign clinical manifestations known as
skin warts (papilloma), ii) mucosal HPV types inducing be-
nign papilloma, intraepithelial neoplastic and invasive can-
cer in the anogenital mucosa as well as in the respiratory
(sinonasal, larynx, trachea, bronchus) and upper digestive
tract (oral mucosa, oropharynx, esophagus) [3]. Of all
HPV-associated malignancies, cervical cancer (CC) is un-
doubtedly the most important causing significant morbidity
and mortality worldwide [3–5]. Given this plurality of HPV
lesions in different anatomic sites, HPV types inducing
asymptomatic or transient infections may use distinct
strategies for transmission and propagation within the* Correspondence: longatto16@hotmail.com
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creativecommons.org/publicdomain/zero/1.0/epithelium, and also for their interactions with the im-
mune system [6].
HPV is the causal agent, necessary for the development
of CC, and identified in practically all cases when highly
sensitive detection methods are used. Cancer development
is associated with HPV persistence that leads to cellular
transformation, disease progression to precancerous le-
sions and, if uninterrupted, to an invasive cancer [7, 8].
HPV types infecting genital mucosa (in both genders)
are subdivided into high-risk (hr) and low-risk (lr) groups.
This classification is based on established epidemiological
evidence on their association with benign, precancerous
and cancer lesions. The hr-HPV are 16, 18, 31, 33, 35, 39,
45, 51, 52, 56, 58 and 59; whereas the lr HPVs include 6,
11, 40, 42, 43, 44, 54, 61, 70, 72 and 81. It is now obvious
that both hr- and lr-HPV infections do occur in different
anatomic sites, inducing either benign, premalignant or
malignant lesions [3, 5, 6, 9].Human papillomavirus life cycle
The HPV life cycle is intimately linked with the pro-
grammed differentiation process of stratified squamous
epithelia (cutaneous and mucosal), starting from the
undifferentiated cells of the basal layer, capable of con-
tinuously dividing, and progressing through highly spe-
cific cellular events towards fully matured keratinocytesrticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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three major phases. First, infectious virions access the
basal layer through a micro-lesion, forming a virus reser-
voir where the viral genome is conserved as a low–copy
number episomal form within the infected cell. Second,
the viral genome replication occurs, whereby host cell
DNA and the infected cells are divided into daughter cells,
which can persist in the basal and parabasal layers and
proceed to the division, or move and initiate the differenti-
ation process. In the latter, activation of the late (L) gene
expression and vegetative viral DNA amplification begin.
This amplification leads to synthesis of a huge number of
viral copies [6, 10, 11]. During hr-HPV infections, degrad-
ation of p53 and inhibition of pRb proteins by E6 and E7
viral proteins, respectively, promotes infected cell prolifer-
ation. These events are a critical determinant of the neo-
plastic grade, E6 and E7 expression levels being high in
CIN 3 and low in CIN 1 lesions [4, 6, 12, 13].
Recent insights into HPV infections
HPV infection is most easily transmitted in sexual inter-
course, and the risk is higher in women with an early onset
of sexual activity (due to higher exposure to the virus) as
well as in those with impaired immunity [14–16]. Cervical
intraepithelial neoplastic (CIN) and CC have been causally
linked with HPV infection, which is considered the neces-
sary prerequisite for the malignant transformation [17].
Virus entry is considered to take place in the basal cells of
the squamous epithelium, specifically at the cervical trans-
formation zone (TZ), where squamous epithelium meets
the glandular epithelium of the endocervical canal. HPV-
induced cell transformation is mediated by the viral E6
and E7 oncoproteins interfering with the cell cycle regula-
tors of the host cells, starting at the basal cells layer and
gradually extending to the full epithelial thickness [9, 18].
Once the infection is well established, the HPV genome
is present as extra-chromosomal elements (episomes)
in the nucleus, and the viral genome load is increased
up to 50–100 copies per cell, while remaining high in
the infectious phase [19, 20].
Natural history of HPV infections
The great majority of sexually active women and men
are likely to be infected by HPV at least once in their
life-time [21]. In general, the vast majority of all HPV in-
fections (90 %) are cleared without clinical diseases,
spontaneously by means of immune response and do
not persist long enough to cause oncogenic progression.
Only about 10 % of HPV infections are expected to re-
main persistent [3, 21]. Individuals who develop benign
lesions may also show regression mediated by the host
immune response. About 50 % of the new infections are
not detected before of 6–12 months and the majority of
those will clear within 24 months. According to anotherconcept on regression, the viral genome remains “latent”
and may be reactivated by any trigger related e.g. to im-
mune suppression or alterations of hormonal balance.
When truly persistent, HPV infection bears a signifi-
cantly increased risk for progression to high-grade lesion
(CIN3) and CC during the years, if not adequately
treated [3, 6, 9, 15, 16, 22].
Around 70 % of all CC cases are associated with hr-
HPV 16 and 18, in contrast to benign genital warts, which
are predominantly related to HPV 6 and 11. Of all hr-
HPV genotypes, HPV 16 shows the highest probability for
persistence, and thus has a major impact on the cancer
risk. HPV 18 is the most frequent genotype found in
adenocarcinomas [3, 6]. Up to 40 % of HPV infections are
of mixed type, containing more than one HPV type. For
this reason, the precise identification of the hr-HPV geno-
types in HPV infections is important to disclose the
woman at risk to develop CC. Despite the fact that also
the majority of these infections clear spontaneously, per-
sistent infections by oncogenic HPV are considered as a
significant risk factor to CC [3, 21, 23].
Cervical cancer incidence
According to the estimates for 2012, more than 528,000
incident cases and 266,000 deaths due to CC were de-
tected worldwide [5]. About 85 % of these cases and 87 %
total deaths occur in the developing countries, mainly due
to poor access to health care for detection and treatment
of early lesions [5]. The high-risk areas, with ASRs over 30
per 100,000 are Eastern Africa (42.7), Melanesia (33.3),
Southern Africa (31.5) and Middle Africa (30.6) (Fig. 1).
Brazilian figures comprise 24,500 incident cases and over
11,000 annual deaths (Fig. 2), with a mortality rate of 17
per 100,000 women [24–27].
The screening strategy in Brazil is targeted to women
aged between 25 and 64 years, repeated every 3 years. Ac-
cordingly, the women should have Pap smear taken each
three years if she has two consecutive normal smears in the
previous screening rounds [28]. In the country, the mean
age of detecting incident HPV infection, CIN3 and CC is
about 20–, 30- and 40 years, respectively. The majority of
the pre-malignant and malignant lesions affect squamous
epithelium, where HPV types 16 and 18 predominate, the
latter being relatively more important in glandular lesions
(adenocarcinomas and their precursors) [14].
HPV detection in preventing cervical cancer
It is established that an organized population-based screen-
ing and treatment of the detected precursor lesions can de-
crease the disease mortality by 80 %, as shown e.g. in
Finland [3, 21]. CC progresses relatively slowly, and it takes
years or even decades from an incident HPV infection
to develop an invasive cancer. This slow process offers
an opportunity to interfere with this cascade by detecting
Fig. 1 Global Incidence and Mortality of Cervical Cancer. Adapted from Globocan, 2012
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[3, 14, 21, 25, 29].
The first national initiative by the Brazilian govern-
ment to implement a national screening program for CC
was taken 40 years ago [30]. Since then, these programs
have been improved and intensified, particularly during
the past few years. A careful weighting is needed to
optimize the program, i.e., to decide who are screened
and when, based on a careful analysis between advan-
tages and disadvantages, including the issues related to
optimal cost-effectiveness.
Since its introduction, the cytological Papanicolaou
smear (Pap test) has been considerate as the method-of-Fig. 2 Estimated age-standardized incidence and mortality rates of Cervicachoice in organized screening for CC. When implemented
as an organized program at population level, Pap smear
screening has resulted in a substantial decrease of both in-
cidence and mortality of CC [3, 21, 31]. In Brazil, there re-
mains a lack of trained professionals with good skills in
evaluating the Pap smears. Along with the huge territory,
which represents another important obstacle, the scanty
financial resources have been the limiting step in the full
national implementation of Pap smear screening. Because
of the same type of restrictions, most other developing
countries continue showing high incidence and mortality
rates of CC, in sharp contrast to many developed coun-
tries, with significantly reduced rates [21, 31, 32].l Cancer in Brazilian population. Adapted from Globocan, 2012
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Brazil has not implemented an organized population-
based CC screening program, and not even a universal
system to invite all women to realize these examinations.
However, the government has designed a program to
identify and control the cytopathology examinations per-
formed. The first examination used to identify CC precur-
sor lesions is the Pap test, targeted to women from
25 years (sexually active) to 64 years, repeated every 3 years
for women who had two consecutive negative smears
within five years. However, the guidelines (national and
international) do not recommend screening for women
younger than 25 years by Pap test, mainly because most of
these lesions clear spontaneously [30, 33].
Recognition that HPV infection is the necessary cause
of CC opened new possibilities for prevention strategies,
including the primary prevention with highly effective
prophylactic HPV vaccines, and the secondary preven-
tion using highly sensitivity HPV tests, which has signifi-
cantly improved the performance of the screening
programs based on the Pap test [33–35].
Molecular techniques have been considered better
than cytology regarding the sensitivity and reproducibil-
ity in detecting CIN 2 or CIN 3. Proper treatment of the
precursor lesions detected by screening should prevent
the development of invasive CC and reduce the inci-
dence and mortality. Some HPV tests used in screening
have achieved a 60–70 % reduction in invasive CC inci-
dence as compared with cytology alone [36]. Despite
some test limitations, HPV testing can be a useful tool
in the primary screening, including the self-sampling
strategies. It has been demonstrated that baseline HPV-
negative women have a lower risk to develop CIN and
invasive CC if compared with women testing Pap smear
negative. The most recent HPV test equipment and pro-
tocols are user-friendly procedures, easily reproducible
in different settings. This is a major advantage, because
many regions of Brazil are still lacking human resources,
necessary to appropriately implement the Pap test, in-
cluding qualified professionals and adequate quality con-
trol measures. However, the non-organized Brazilian
program severely restricts the implementation of a sys-
tematic molecular screening by HPV tests that are
already in widespread use in many developed countries.
This implementation is hampered by the difficulties in
confirming the diagnoses, to conduct follow-up and offer
treatment of the detected cervical lesions [36–38].
During the past several years, a plethora of novel
methods have been developed for the hr-HPV DNA testing
in CC screening. The use of HPV DNA testing for onco-
genic types has been proposed as a co-test with cytology
for screening women above 30 years of age, showing higher
accuracy as conventional Pap smear screening [17, 39–41].
Thus, HPV DNA testing could offer an effective measureto predict the risk of CC, suitable for implementation also
in regions with lower resources [42]. Furthermore, self-
collection of vaginal specimens for HPV testing could be
useful particularly for women who live in regions with low-
resource settings and restricted access to adequate health
care, like in many regions of Brazil, thus increasing the ac-
ceptability and coverage of the screening program. How-
ever, HPV DNA testing is not yet a routine in Brazil,
despite the fact that several studies in Brazilian population
have demonstrated its potential usefulness in CC preven-
tion [20, 43, 44].
The overall acceptance of HPV testing is higher
among women who have experience on self-sampling
(made at home), as compared with the physician collec-
tion [40]. Moreover, the self-sampling has lower cost
and it is a truly non-invasive procedure. However, the
gold standard of HPV testing still is the sampling by a
physician (using speculum examination) [40, 45].
Which type of screening for which population?
For almost 60 years now, cervical cytology (conventional
Pap smear and more recently LBC), has been the gold
standard in CC screening programs. Based on early de-
tection of CC precursor (CIN) lesions, both tests repre-
sent measures of secondary prevention of CC. However,
organized screening based on cervical cytology has se-
vere limitations in implementation; extensive training is
mandatory, good laboratory infrastructure is necessary, and
standardization and quality control are essential [14, 42, 46].
The well-established natural history of HPV infections
is the sound basis for the rational use of CC preventive
measures based on HPV testing. The single most im-
portant goal of CC screening is to reduce mortality. This
is achieved by decreasing the incidence of invasive dis-
ease by detecting the precancerous lesions, followed by
their adequate treatment [9, 46, 47]. Ronco et all (2008)
concluded that women aged 25–34 years, who test HPV+
in HPV DNA screening do not need an immediate referral
to colposcopy, because of the high probability of spontan-
eous regression of even CIN 2 lesions in this age group.
Combination of HPV DNA testing and cytology further
decreases the rate of false-positive results, thus reducing
the colposcopy referral rates [17, 48]. Similarly, one can
expect a substantial decrease of false-negative results (the
inherent problem of cytology) when HPV screening is
used, which is another advantage with significant impact
on screening efficacy.
The vaccination and screening paradigm
Although HPV vaccination of teenagers and young
women has proven effective in many countries, the pub-
lic health strategies to demonstrate effective prevention
of CC still represent major obstacles to overcome. The
cost-effectiveness analysis for all strategies to reduce CC
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vaccination in an integrated and organized manner. At
the moment, the preferable option in Brazil seems to be
the use of HPV testing for primary screening, followed
by triage of all HPV+ cases with the Pap test. A recent
Mexican trial [49] showed a most marked improvement
in CC prevention when HPV test was used in govern-
mental program, which sounds feasible given the known
limitations of the Pap test. Indeed, the expected reduc-
tion of high-grade lesions after widespread introduction
of HPV vaccination is anticipated to further compromise
the performance of Pap test [49, 50].
According to WHO, HPV types 16 and 18 are respon-
sible for 70 % of all CC cases worldwide. The currently
available vaccines against these two HPV types have the
potential of reducing the incidence of cervical and ano-
genital cancer. Brazil has a population of >64 million
women aged above 15 years and at risk to develop CIN
and CC, who certainly would benefit from HPV vaccines
[29]. In this country, National Health System adopted the
quadrivalent HPV vaccine to the national vaccination pro-
gram in 2014. The vaccine is offered for girls at 11–13
years of age. This age range was extended to cover girls
aging 9 and 10 years, and the coverage includes more than
33,000 HIV positive women between 9–26 years [35].
With the widespread implementation of HPV vaccines,
HPV infections and HPV-related lesions will decrease
substantially, which might increase the rates of false-
negative results in cytology, in addition to reduced speci-
ficity. The combination of HPV vaccination with HPV
testing and cytological triage is suggested to be the opti-
mal algorithm to protect women against CC [16, 34, 47].
Conclusions
The most important applications of HPV testing include i)
organized screening programs to optimize an early detec-
tion of HPV-induced CC precursor lesions, and, ii) to con-
duct adequate follow-up of the women who have been
treated for high-grade CIN.
Some novel technical innovations of HPV testing are
particularly designed for remote areas, without comprom-
ising the test performance for hr-HPV detection. Certainly
self-sampling for HPV testing still needs standardization
to make it compatible with the usual sampling techniques.
Once successfully accomplished, it has a potential to be-
come a valuable screening tool for large underprivileged
populations, thus contributing to alleviating the significant
disease burden in these countries.
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